Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2018-09-10 16:45:40
Reporting Period:
Accepted Time:
2018-09-10 16:45:40
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1621227 Adaptimmune Therapeutics Plc ADAP () 4
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1219855 James M Barrett 1954 Greenspring Drive
Suite 600
Timonium MD 21093
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares With A Nominal Value Of 0.001 Gbp Per Share Acquisiton 2018-09-07 3,000,000 $1.67 82,978,668 No 4 P Indirect See Note 3
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Note 3
  1. The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.
  2. The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six.
  3. The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of NEA 14, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the Reporting Person has no pecuniary interest.